相关实验视频

Updated: Jun 5, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

持久或抵抗:在EGFR突变NSCLC中的免疫检查点抑制剂

Pengcheng Zhu^1,2, Zhitong Li^1,2, Yuxiang Sun^1,2

¹Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.

|December 14, 2024

概括

免疫检查点抑制剂 (ICI) 作为对具有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 的单一疗法具有有限的益处. 需要进一步的研究来确定可能对EGFR突变NSCLC的ICI反应的患者子组.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKIs) 改善了EGFR突变非小细胞肺癌 (NSCLC) 的存活率,但耐药性很常见.
免疫检查点抑制剂 (ICI) 有利于EGFR野生型NSCLC,但在EGFR突变NSCLC单一治疗中表现出有限的疗效.
在瘤突变负担 (TMB),PD-L1表达和免疫微环境方面,EGFR突变的NSCLC表现出显著的异质性.

研究的目的:

审查ICI或EGFR突变NSCLC患者的组合疗法的临床试验.
讨论影响ICI在这个患者群体中的疗效的因素.
探索潜在ICI响应者的突变亚型和免疫微环境特征.

主要方法:

对涉及EGFR突变NSCLC的ICI的临床试验进行系统审查.
分析影响ICI疗效的因素,包括TMB,PD-L1和免疫微环境.
突变亚型和微环境与治疗反应的相关性.

主要成果:

在EGFR突变的NSCLC中,ICI单疗没有显示出显著的生存益处.
经EGFR突变的NSCLC呈现出多样化的免疫特征,影响ICI反应.
在EGFR突变的NSCLC中确定ICI疗效的预测生物标志物至关重要.

结论:

在EGFR突变的NSCLC中ICI的作用需要进一步阐明.
考虑到瘤异质性的个性化治疗策略至关重要.
未来的研究应该集中在组合疗法和确定预测生物标志物,以实现最佳的患者选择.

关键词:

作为 EGFR 氨酸激酶抑制剂 (TKI) 的皮肤上生长因子受体 (EGFR)免疫检查点抑制剂 (ICI)非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.瘤免疫学瘤免疫学

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...